Aveanna Healthcare Reports Strong Q4 & Full Year 2025 Results, Maintains 2026 Guidance

summarizeSummary

Aveanna Healthcare Holdings reported significant revenue and Adjusted EBITDA growth for Q4 and full year 2025, turning a net loss into substantial net income, and reaffirmed its full year 2026 guidance.

check_boxKey Events

• Strong Q4 2025 Financial Performance

  Revenue increased 27.4% to $662.5 million, and Adjusted EBITDA grew 54.0% to $85.0 million compared to the prior year period. Net income was $178.8 million.

• Significant Full Year 2025 Results

  Revenue rose 20.2% to $2.43 billion, and Adjusted EBITDA surged 74.8% to $320.9 million. The company reported a net income of $225.0 million, a significant turnaround from a net loss in the prior year.

• Maintained Full Year 2026 Guidance

  Aveanna reaffirmed its full year 2026 revenue guidance of $2.54 to $2.56 billion and Adjusted EBITDA guidance of $318 to $322 million, indicating confidence in future performance.

• Strong Free Cash Flow Generation

  The company generated $131.0 million in free cash flow for fiscal year 2025, further strengthening its balance sheet.

auto_awesomeAnalysis

Aveanna Healthcare Holdings delivered robust financial performance for the fourth quarter and full fiscal year 2025, demonstrating strong operational momentum. The company achieved substantial increases in revenue and Adjusted EBITDA, notably converting a prior year net loss into a significant net income for the full year. Maintaining its full year 2026 revenue and Adjusted EBITDA guidance signals management's confidence in continued growth and operational efficiency. This positive earnings report, following a recent acquisition announcement, reinforces the company's strategic transformation and financial health.